Ann-Sofie De Meulemeester

Jan 11, 2025 | mdpi.com | Sebastiaan ter Horst |Aleksandra Siekierska |Ann-Sofie De Meulemeester |Arno Cuvry

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 23, 2024 | onlinelibrary.wiley.com | Ann-Sofie De Meulemeester |Institut du Cerveau |Christopher Reid |Stéphane Auvin

CONFLICT OF INTEREST STATEMENT SA is deputy editor for Epilepsia. He has served as a consultant or received honoraria for lectures from Angelini Pharma, Biocodex, BioMarin, Encoded, Eisai, GRIN Therapeutics, Jazz Pharmaceutics, Neuraxpharm, Nutricia, Orion, UCB Pharma, Xenon, and Zogenix. He has been an investigator for clinical trials for Eisai, Marinus, Proveca, UCB Pharma, Xenon and Zogenix. S.L.M. was associate editor of Neurobiology of Disease until December 2021.